Even in settings in which EZH2 inhibition proved remarkably effective, as in lymphomas with gain-of-function mutations, it was not possible to define consistent transcriptional outputs, indicating that Polycomb can regulate different pathways even within the same apparently homogeneous tumour type15. Here, EZH2 is linked to neoplasm.